Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 220.7 Billion KRW | 27.04% |
| 2022 | 173.72 Billion KRW | 896.14% |
| 2021 | 17.44 Billion KRW | 2.87% |
| 2020 | 16.95 Billion KRW | -3.93% |
| 2019 | 17.64 Billion KRW | -73.49% |
| 2018 | 66.55 Billion KRW | -17.24% |
| 2017 | 80.41 Billion KRW | 59.01% |
| 2016 | 50.57 Billion KRW | 189.37% |
| 2015 | 17.47 Billion KRW | -23.06% |
| 2014 | 22.71 Billion KRW | 4.62% |
| 2013 | 21.71 Billion KRW | -11.65% |
| 2012 | 24.57 Billion KRW | -42.64% |
| 2011 | 42.84 Billion KRW | 19.37% |
| 2010 | 35.89 Billion KRW | 5.91% |
| 2009 | 33.89 Billion KRW | 180.53% |
| 2008 | 12.08 Billion KRW | -42.24% |
| 2007 | 20.91 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 218.74 Billion KRW | -6.42% |
| 2024 Q1 | 233.73 Billion KRW | 5.9% |
| 2023 Q3 | 203.46 Billion KRW | 32.73% |
| 2023 Q2 | 153.28 Billion KRW | -11.88% |
| 2023 FY | 220.7 Billion KRW | 27.04% |
| 2023 Q1 | 173.95 Billion KRW | 0.13% |
| 2023 Q4 | 220.7 Billion KRW | 8.47% |
| 2022 Q1 | 18.6 Billion KRW | 6.69% |
| 2022 FY | 173.72 Billion KRW | 896.14% |
| 2022 Q4 | 173.72 Billion KRW | 586.69% |
| 2022 Q3 | 25.29 Billion KRW | 40.04% |
| 2022 Q2 | 18.06 Billion KRW | -2.91% |
| 2021 FY | 17.44 Billion KRW | 2.87% |
| 2021 Q4 | 17.44 Billion KRW | 11.03% |
| 2021 Q1 | 17.16 Billion KRW | 1.25% |
| 2021 Q2 | 16.82 Billion KRW | -1.95% |
| 2021 Q3 | 15.7 Billion KRW | -6.67% |
| 2020 FY | 16.95 Billion KRW | -3.93% |
| 2020 Q4 | 16.95 Billion KRW | -14.05% |
| 2020 Q3 | 19.72 Billion KRW | -6.19% |
| 2020 Q1 | 19.82 Billion KRW | 12.35% |
| 2020 Q2 | 21.02 Billion KRW | 6.06% |
| 2019 Q2 | 53.1 Billion KRW | 1.32% |
| 2019 Q4 | 17.64 Billion KRW | -28.5% |
| 2019 FY | 17.64 Billion KRW | -73.49% |
| 2019 Q1 | 52.41 Billion KRW | -21.24% |
| 2019 Q3 | 24.67 Billion KRW | -53.53% |
| 2018 Q2 | 65.38 Billion KRW | -13.47% |
| 2018 Q3 | 65.64 Billion KRW | 0.41% |
| 2018 FY | 66.55 Billion KRW | -17.24% |
| 2018 Q4 | 66.55 Billion KRW | 1.37% |
| 2018 Q1 | 75.55 Billion KRW | -6.03% |
| 2017 Q4 | 80.41 Billion KRW | -13.99% |
| 2017 FY | 80.41 Billion KRW | 59.01% |
| 2017 Q3 | 93.49 Billion KRW | 82.43% |
| 2017 Q2 | 51.24 Billion KRW | -4.61% |
| 2017 Q1 | 53.72 Billion KRW | 6.23% |
| 2016 FY | 50.57 Billion KRW | 189.37% |
| 2016 Q2 | 47.14 Billion KRW | 55.97% |
| 2016 Q3 | 47.51 Billion KRW | 0.8% |
| 2016 Q4 | 50.57 Billion KRW | 6.42% |
| 2016 Q1 | 30.22 Billion KRW | 72.96% |
| 2015 Q3 | 17.49 Billion KRW | 2.8% |
| 2015 Q4 | 17.47 Billion KRW | -0.12% |
| 2015 Q1 | 23.83 Billion KRW | 4.92% |
| 2015 Q2 | 17.02 Billion KRW | -28.59% |
| 2015 FY | 17.47 Billion KRW | -23.06% |
| 2014 Q2 | 27.4 Billion KRW | -12.21% |
| 2014 Q1 | 31.22 Billion KRW | 43.8% |
| 2014 FY | 22.71 Billion KRW | 4.62% |
| 2014 Q4 | 22.71 Billion KRW | -14.48% |
| 2014 Q3 | 26.56 Billion KRW | -3.09% |
| 2013 Q4 | 21.71 Billion KRW | 10.18% |
| 2013 FY | 21.71 Billion KRW | -11.65% |
| 2013 Q3 | 19.7 Billion KRW | -4.01% |
| 2013 Q2 | 20.53 Billion KRW | 1.91% |
| 2013 Q1 | 20.14 Billion KRW | -18.03% |
| 2012 FY | 24.57 Billion KRW | -42.64% |
| 2012 Q4 | 24.57 Billion KRW | 0.0% |
| 2012 Q1 | 34.95 Billion KRW | 0.0% |
| 2011 Q1 | 31.58 Billion KRW | 0.0% |
| 2011 FY | 42.84 Billion KRW | 19.37% |
| 2011 Q3 | 39.93 Billion KRW | 28.38% |
| 2011 Q2 | 31.1 Billion KRW | -1.53% |
| 2010 Q1 | 29.68 Billion KRW | 4.99% |
| 2010 FY | 35.89 Billion KRW | 5.91% |
| 2010 Q2 | 23.82 Billion KRW | -19.76% |
| 2009 Q4 | 28.27 Billion KRW | 0.0% |
| 2009 FY | 33.89 Billion KRW | 180.53% |
| 2009 Q2 | 21.57 Billion KRW | 114.59% |
| 2009 Q1 | 10.05 Billion KRW | 7.59% |
| 2008 FY | 12.08 Billion KRW | -42.24% |
| 2008 Q2 | 20.35 Billion KRW | -9.01% |
| 2008 Q1 | 22.36 Billion KRW | 3.58% |
| 2008 Q4 | 9.34 Billion KRW | 0.0% |
| 2007 Q1 | 15.22 Billion KRW | 0.0% |
| 2007 Q2 | 15.06 Billion KRW | -1.06% |
| 2007 FY | 20.91 Billion KRW | 0.0% |
| 2007 Q4 | 21.59 Billion KRW | 3.24% |
| 2007 Q3 | 20.91 Billion KRW | 38.86% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -183.472% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 76.263% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 68.787% |
| HANDOK Inc. | 449.7 Billion KRW | 50.922% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -157.621% |
| Yuhan Corporation | 712.33 Billion KRW | 69.017% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 65.073% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -1288.565% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 74.09% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -312.312% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -7.203% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -193.604% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -49.333% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -213.496% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -183.472% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -505.73% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 12.123% |
| JW Holdings Corporation | 827.51 Billion KRW | 73.329% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 49.495% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 62.388% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 41.858% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -178.312% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -215.439% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 9.12% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 33.179% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -183.472% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 54.96% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 74.278% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 41.858% |
| Yuhan Corporation | 712.33 Billion KRW | 69.017% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 53.809% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -61.136% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 57.283% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 41.858% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -42.818% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -145.323% |
| CKD Bio Corp. | 170.76 Billion KRW | -29.248% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 9.448% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -39.991% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -413.039% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -178.312% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 65.107% |
| Boryung Corporation | 373.1 Billion KRW | 40.847% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -6.008% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -7.203% |
| JW Lifescience Corporation | 96.44 Billion KRW | -128.845% |